ModernGraham Valuation

Company Name:

Company Ticker RMD Date of Analysis ResMed Inc.



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

3/8/2019

Defensive Investor; must pass 6 out of the following 7 tests.

1.	Adequate Size of the Enterprise	Market Cap > \$2Bil	\$14,454,671,393	Pass
2.	Sufficiently Strong Financial Condition	Current Ratio > 2	2.44	Pass
3.	Earnings Stability	Positive EPS for 10 years prior		Pass
4.	Dividend Record	Dividend Payments for 10 years prior		Fail
5.	Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	74.20%	Pass
6.	Moderate PEmg Ratio	PEmg < 20	39.26	Fail
7.	Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	7.46	Fail
Enterprising Investor; mus	t pass 4 out of the following 5 tests, or be s	uitable for the Defensive Investor.		

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	2.44 Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	1.89 Fail
3. Earnings Stability	Positive EPS for 5 years prior	Pass
4. Dividend Record	Currently Pays Dividend	Pass
5. Earnings Growth	EPSmg greater than 5 years ago	Pass
	Score	

Suitability

Defensive	No
Enterprising	Yes

Stage 2: Determination of Intrinsic Value

	EPSmg		\$2.57
	MG Growth Estimate		2.51%
	MG Value		\$34.82
	MG Value based on 3% Growth		\$37.32
	MG Value based on 0% Growth		\$21.88
	Market Implied Growth Rate		15.38%
MG Opinion			
	Current Price		\$101.06
	% of Intrinsic Value		290.28%
	Opinion	Overvalued	
	MG Grade	С	


Stage 3: Information for Further Research


Net Current Asset Value (NCAV)	-\$5.82
Graham Number	\$31.42
PEmg	39.26
Current Ratio	2.44
PB Ratio	7.46
Current Dividend	\$1.40
Dividend Yield	1.39%
Number of Consecutive Years of Dividend Growth	6
	•

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate		Next Fiscal Year Estimate	\$2.57
Jun2018	\$2.19	Jun2018	\$2.36
Jun2017	\$2.40	Jun2017	\$2.42
Jun2016	\$2.49	Jun2016	\$2.36
Jun2015	\$2.47	Jun2015	\$2.20
Jun2014	\$2.39	Jun2014	\$1.97
Jun2013	\$2.10	Jun2013	\$1.67
Jun2012	\$1.71	Jun2012	\$1.37
Jun2011	\$1.44	Jun2011	\$1.12
Jun2010	\$1.23	Jun2010	\$0.90
Jun2009	\$0.95	Jun2009	\$0.70
Jun2008	\$0.70	Jun2008	\$0.55
Jun2007	\$0.43	Jun2007	\$0.46
Jun2006	\$0.58	Jun2006	\$0.46
Jun2005	\$0.46	Jun2005	\$0.37
Jun2004	\$0.41	Jun2004	\$0.30
Jun2003	\$0.33	Jun2003	\$0.23
Jun2002	\$0.28	Balance Sheet Information	12/1/2018
Jun2001	\$0.09	Total Current Assets	\$1,063,539,000
Jun2000	\$0.17	Total Current Liabilities	\$436,443,000
Jun1999	\$0.13	Long-Term Debt	\$1,185,500,000
		Total Assets	\$3,859,816,000
		Intangible Assets	\$2,243,971,000
		Total Liabilities	\$1,903,772,000
		Shares Outstanding (Diluted Average)	144,349,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company #N/A

Other ModernGraham posts about related companies Cooper Companies Inc Valuation – March 2019 #COO Edwards Lifesciences Corp Valuation – March 2019 \$BW Boston Scientific Corporation Valuation – March 2019 \$BSX Baxter International Inc Valuation – March 2019 \$BAX Centene Corp Valuation – March 2019 \$CNC Abbott Laboratories Valuation – February 2019 \$ABT Becton Dickinson and Co Valuation – February 2019 \$BDX IQVIA Holdings Inc Valuation – February 2019 \$IQV Thermo Fisher Scientific Inc Valuation – February 2019 \$ILMN